openPR Logo
Press release

Bivalirudin Drug Market Challenging Health Concerns 2025 | The Medicines Company, Pfizer

07-11-2019 02:06 PM CET | Health & Medicine

Press release from: TMR Research

TMR Research

TMR Research

Bivalirudin Drug Market Introduction

Bivalirudin is a synthetic residue peptide and it is direct thrombin inhibitor (DTI). It is an anticoagulant that helps to prevent the formation of blood clots, especially in people with severe chest pain or ones who are undergoing angioplasty. Bivalirudin is for IV use only and it is supplied as a sterile, lyophilized product, and glass vials. Moreover, Bivalirudin is also used conjuction with other medicines.

Get Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4818

Bivalirudin drugs are finding wide application in patients undergoing Percutaneous Transluminal Coronary Angioplasty (PTCA) and percutaneous coronary intervention (PCI) procedures. Bivalirudin is not given to patients with active major bleeding. The most common adverse health effects of Bivalirudin are pain, nausea, back pain, hypotension, and headache. Meanwhile, Bivalirudin is also approved for cardiac patients undergoing PCI. Bivalirudin is also partly cleared by renal mechanism, hence, the dose administration needs to be managed for patients with severe renal impairment.

Bivalirudin Drug Market: Notable Developments

Accord Healthcare has entered into the license agreement with Foresee Pharma. Under the agreement, Foresee will receive combination of regulatory, sales and upfront milestone, in addition to the significant share of the product revenue as Accord Healthcare will cover overall cost of commercialization in the global market with exception of Japan, mainland China, the US, and Taiwan, along with previously partnered territories including various countries in the Middle East, Turkey, and Israel.
Aurobindo Pharma has acquired Apotex’s commercial operations in five European countries including the Netherlands, Belgium, Poland, Spain, and the Czech Republic.
Beximo Pharmaceuticals Limited plans to buy eight ANDAs in the US from Sandoz Inc., a division of Novartis. Following this deal, Beximo Pharma will have 14 approved ANDAs in its product portfolio in the US.
Some of the leading players operating in the Bivalirudin drug market are Sandoz, Dr. Reddys Laboratories, Fresenius Kabi, Apotex, The Medicines Company, Pfizer, Aurobindo Pharma, Mylan, Accord Healthcare, Sun Pharmaceuticals Industries Limited, and Ferring Pharmaceuticals.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=4818

Bivalirudin Drug Market Dynamics

Bivalirudin Drug as Alternative to Heparin for Anticoagulation in Children and Infants

Bivalirudin has emerged as an alternative for heparin for infants and children in anticoagulation. Moreover, Bivalirudin, unlike heparin, does not require antithrombin to be effective, thus providing more consistent anticoagulation. The use of DTI among children and infants has been uncommon. However, the primary reason for use of DTI is the development of thrombus or HIT extension during the heparin therapy.

Although the use of Bivalirudin is not common in pediatrics, the use of DTI is slowly increasing owing to the rise in diagnosis of HIT. Meanwhile, in various studies, researchers have found a significant reduction in the rate of bleeding after using DTI with Bivalirudin as compared to argatroban. Meanwhile, the first pilot study on use of Bivalirudin to treat thrombosis in infants was presented in 2007. After this more research has been done resulting in the successful use of Bivalirudin in various cases including children undergoing cardiac catheterization.

Increasing Use of Bivalirudin Drug in Patients Undergoing PCI

The acute coronary syndrome is emerging as the most common cause of death globally. This is driving the demand for Percutaneous Coronary Intervention (PCI) to manage acute coronary syndrome. In order to reduce the risk of thrombotic complications, the use of anticoagulation therapy is increasing during PCI, thereby, driving the demand for Bivalirudin drug as the anticoagulant drug as it reduces the risk of bleeding during the procedure. Moreover, Bivalirudin drug has also been licensed as an alternative to Heparin for the patients undergoing PCI and also for the patients with HIT who go for PCI.

The sale of Bivalirudin drug is also increasing as anticoagulant drug owing to the advantages as compared to similar drugs in the market. Moreover, Bivalirudin does not present complications including hemorrhagic and ischemic that are often caused by other anticoagulant drugs.

High Cost of Bivalirudin Drug to Restrain its Growth

Despite increasing use of Bivalirudin drug as a substitute for Heparin and other anticoagulant drugs, the high cost of Bivalirudin drug is restricting its use among patients with low or moderate risk of bleeding. Although, Bivalirudin has shown better results in patients undergoing PCI, its high cost may restrict its use among patients. Moreover, expenditure review by various healthcare institutions have also noted a significant increase in the contribution of Bivalirudin drug on the overall drug budget.

Various organizations and governments are focusing on cost saving initiatives to reduce the cost of Bivalirudin and also reduce its wastage by providing the dosage as required depending on the patient’s condition.

Bivalirudin Drug Market Segmentation

Based on the types, the Bivalirudin drug market is segmented into

Ready-to-use solution
Powder for reconstitution

On the basis of application, the Bivalirudin drug market is segmented into

Drug store
Hospital

By end use the Bivalirudin drug market is segmented into

Percutaneous Coronary Intervention (PCI) Procedures
Percutaneous Transluminal Coronary Angioplasty (PTCA) Procedures
Others

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bivalirudin Drug Market Challenging Health Concerns 2025 | The Medicines Company, Pfizer here

News-ID: 1802052 • Views: 70

More Releases from TMR Research

Configuration Management Market 2018-2028 | CA Technologies, BMC Software, Oracl …
Global Configuration Management Market: Overview The demand within the global configuration management market is rising on account of advancements in the domain of product analysis and optimization. Development of a product or system is followed by a rigorous process of optimization to increase the efficiency and life of the system. The need to retain the utility and effectiveness of products has created tremendous demand within the global configuration management market. The
Security Orchestration Automation and Response Market | Qualitative Opportunitie …
Global Security Orchestration Automation and Response Market: Overview The demand within the global security orchestration automation and response is growing on account of advancements in the field of organizational security. The need to protect data and key assets across companies and organizations has played an integral role in the growth of the global security orchestration automation and response market. Furthermore, the growing level of automation across industrial and commercial units has
Global AI in Fashion Market Overview, Development, Segment by Type, Application …
AI in Fashion Market: Overview The global market for AI in fashion is expected to witness a stellar growth in coming few years. The market is expected flourish due to emergence of several fashion trends all across the globe. Fashion across the globe keeps on changing at a moment’s notice. It has become incredibly hard to keep a solid track of all the important fashion related activities. This has been a
Crowdsourced Security Market 2018 - 2028 | TMR Research
Crowdsourced Security Market: Overview The global crowdsourced security market is expected develop at a healthy pace in the coming years of the forecast period of 2018 to 2028. The mobile phone application segment of the crowdsourced security market is expected to develop at a rapid pace in these coming years. The rate of adoption of these mobile application is growing at a great pace and is thus helping the market to

All 5 Releases


More Releases for Bivalirudin

Bivalirudin Drug Market Competitive Landscape by 2028 : Sandoz, Dr. Reddys Labor …
Bivalirudin Drug Market Introduction Bivalirudin is a synthetic residue peptide and it is direct thrombin inhibitor (DTI). It is an anticoagulant that helps to prevent the formation of blood clots, especially in people with severe chest pain or ones who are undergoing angioplasty. Bivalirudin is for IV use only and it is supplied as a sterile, lyophilized product, and glass vials. Moreover, Bivalirudin is also used conjuction with other medicines. Bivalirudin drugs
Detailed Market Research On Bivalirudin Drug Market By Top Key Player And Their …
Up Market Research published a detailed report on “Bivalirudin Drug Market”. The report provides an in-depth overview of industry and competitive landscape, covering multiple market segments and elaborates market outlook and status to 2026. Get Sample Copy Of This Report @ https://www.upmarketresearch.com/home/requested_sample/88192 The report contains 91 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Bivalirudin Drug Market research report
Bivalirudin Industry Outlook to 2023- Sandoz, Fresenius Kabi, Pfizer, Mylan, Dr. …
Feb 2019, New York, USA(News)- In the Global Bivalirudin Industry Market Analysis & Forecast 2018-2023, the revenue is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2023, growing at a CAGR of XX% between 2018 and 2023. The production is estimated at XX million in 2017 and is forecast to reach XX million by the end of 2023, growing
Bivalirudin Drug Market Seeking Out the Highest Visibility and the Best Value in …
Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a direct thrombin inhibitor (DTI). In 2018, the market size of Bivalirudin Drug is xx million US$ and it will reach xx million US in 2025, growing at a CAGR of xx% from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US in 2025, with a CAGR of xx% during
Bivalirudin Market: Find Out Top Impacting Factor of Market Growth By Opportunit …
The 'Global and Chinese Bivalirudin Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Bivalirudin Market with a focus on the Chinese market. The report provides key statistics on the market status of the Bivalirudin manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of
Increasing Cases of Cardiovascular Diseases to Drive the Growth of Bivalirudin a …
“Bivalirudin and Desmopressin Market: Global Demand Analysis & Opportunity Outlook 2024” The global bivalirudin and desmopressin market is segmented into use such as Percutaneous Transluminal Coronary Angioplasty (PTCA) procedures, Percutaneous Coronary Intervention (PCI) procedures and others. Among these segments, Percutaneous Transluminal Coronary Angioplasty (PTCA) procedures segment is expected to occupy top position in overall bivalirudin and desmopressin market during the forecast period. Rising demand for minimally invasive procedure to open up